The EU warn anti-competitive behavior to manufacturers

         EU regulators announced that Johnson and Novartis have accepted a fine of 16.3 million euros ($22 million),because they in order to stop a cheaper generic painkillers marketed.The European Commission also warned anti-competitive behavior to manufacturers.
         This is the second time that European Commission punish the behavior that delayed payment transactions listed.In such agreements,the brand manufacturers pay generic drugs competitorsments,so that the latter do not sell at a lower price generic versions of brand drugs.This is very common in the pharmaceutical industry,which attracted the attention of global regulatory agencies.The agreement will lead the sellers to increase the drug price and improve the public health care costs.
         EU competition Commissioner-JoaquinAlmunia state that on Tuesday,The decision should enable pharmaceutical companies to think again before the conduct of such anti-competitive behavior,this practice undermines the patient and the interests of taxpayers.

By Ann